Contract Option Exercises — May 20, 2026

A firm-fixed-price delivery order for a critical polar satellite mission through 2028 adds a long-duration, high-visibility revenue stream to Northrop Grumman's space segment, reinforcing its competitive moat in large space systems.

A cost-plus-award-fee contract for three flight instrument units through 2031 (potentially 2037) provides low-risk, predictable revenue for RTX's Space & Airborne Systems segment, aligning with long-term government science priorities.

A cost-plus-fixed-fee contract for an antibiotic targeting antimicrobial resistance and biothreat pathogens, with potential value up to $318.6M through 2032, positions Venatorx for sustained revenue in a high-priority national security area.

A firm-fixed-price delivery order for non-intrusive inspection systems shifts cost risk to Leidos, with a long performance period through 2033 and a 22% subaward concentration, increasing potential for margin pressure.

Northrop Grumman's $569.5M firm-fixed-price JPSS-2 contract introduces execution risk on a complex space vehicle program, where cost overruns could compress margins.

9 of 11 contracts are civilian (NASA, HHS, DOI, DHS, State), making the portfolio vulnerable to Continuing Resolution uncertainty and potential budget cuts in non-defense discretionary spending.

Caltech received two NASA contracts totaling $515.4M (28% of aggregate), creating single-recipient concentration risk with no direct public equity exposure.

Magellan Federal's $151.7M DOI contract is time-and-materials with 24 subawards ($45.9M), indicating pass-through work that limits margin upside and suggests low competitive moat for recompete.

Northrop Grumman's JPSS-2 win positions it for follow-on NOAA/NASA polar satellite contracts, a stable budget area for weather and climate monitoring.

Venatorx Pharmaceuticals' BARDA contract for AMR and biothreat pathogens has $246.5M in unexercised options through 2032, offering significant revenue upside if exercised.

SOFTRAMS LLC's $133.7M CMS IT contract (HUBZone set-aside) signals growing government demand for specialized small business IT services, with $65.3M in unexercised options.

Three NASA contracts (Northrop Grumman $569.5M, RTX $200M, Caltech $445M) total $1.21B or 65% of aggregate, demonstrating sustained investment in polar satellites, Earth science instruments, and early-stage space R&D despite broader budget uncertainty.

Four HHS contracts (Venatorx $72.1M, Deloitte $69.7M, SOFTRAMS $68.4M, SELUX $62.6M) total $272.9M, reflecting steady demand for IT modernization and biodefense R&D, though with limited direct equity exposure.

Only 2 of 11 contracts are defense-related (Leidos $98.8M DHS, Magellan Federal $151.7M DOI), and neither is a core DOD award. This contrasts with typical defense-heavy contract flows and may signal a temporary shift or data sample bias.

{"entity"=>"Northrop Grumman", "reason"=>"Largest contract ($569.5M) with firm-fixed-price execution risk on a complex space vehicle program.", "trigger"=>"JPSS-2 delivery milestones and $37.2M option exercise decision"}

{"entity"=>"Venatorx Pharmaceuticals", "reason"=>"BARDA contract with $246.5M in unexercised options for AMR antibiotic, a high-priority biodefense area.", "trigger"=>"Clinical/regulatory milestones and BARDA option exercise announcements"}

{"entity"=>"Leidos", "reason"=>"$98.8M DHS fixed-price contract with 22% subaward concentration and long performance period through 2033.", "trigger"=>"DHS budget appropriations for border security technology and re-compete announcements"}

{"entity"=>"NASA Civilian Budget", "reason"=>"65% of aggregate value tied to NASA; any budget cuts or CR impacts could delay option exercises.", "trigger"=>"FY2027 budget request, CR expiration, NDAA provisions for NASA"}